Moleculin Biotech has entered into an agreement to collaborate with the University of Bergen to expand research on inhibition of brain metastasis by its pre-clinical drug WP1066 and its ability to increase immune system response to cancer and suppression of tumor cell proliferation and survival.
Original Article: Moleculin to collaborate with University of Bergen for immune stimulation drug
NEXT ARTICLE